Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
about
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedDigital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune responseAssociation of DNA Repair Gene APE1 Asp148Glu Polymorphism with Breast Cancer Risk.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.New concepts in breast cancer emerge from analyzing clinical data using numerical algorithmsVariables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancerIs breast cancer the same disease in Asian and Western countries?Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerAssociation of single nucleotide polymorphisms in Wnt signaling pathway genes with breast cancer in Saudi patients.Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.Breast cancer adjuvant therapy: time to consider its time-dependent effects.Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers.Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyAssociation of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.Long-term prognosis of breast cancer detected by mammography screening or other methodsSurvival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.Epidemiology of triple negative breast cancers"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study.Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.Age - specific incidence rate change at breast Cancer and its different histopathologic subtypes in Iran and Western countries.The effect of local therapy on breast cancer mortality: is there an age-interaction?Qualitative age interactions in breast cancer studies: a mini-review.Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa.Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 RandomProspective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.Hormone receptor-negative breast cancer: undertreatment of patients over 80.Estimation of a decreasing hazard of patients with acute coronary syndrome.Time-varying effects of prognostic factors associated with long-term survival in breast cancer.Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study
P2860
Q24610409-069CE40E-C31E-4B1C-B283-B64DF5DDDA96Q28533543-2A04E407-1758-467E-AC73-90F2D1660A7CQ30377712-6B3BD443-DA00-4B1B-A814-E08F243EB177Q33291587-A1A582A0-065E-4BF3-BA60-89717AD69664Q33445553-3F92C042-A55A-4D8E-9634-6F611FC2A10DQ33541305-947BFF5C-52F8-4B38-97FF-95E8135795BEQ34115977-5CFA6D31-19C7-4605-B63C-1EB2719D5952Q34174466-89C5BCFA-8079-4AA3-BD15-525FEA3CAD73Q34630473-998BF880-4969-42C5-BCAC-181F774306CBQ34842494-1111192F-7659-4854-8A9C-1642AAB16B2FQ34918360-19BF0102-460D-4113-8C55-49CC7DD93A04Q35023428-B88B3AA1-F873-4E95-8A67-4085270A363FQ35220437-5B3C44DA-CECE-4958-9373-CD3FEA305756Q35580011-DC210CE8-59DE-4970-9D14-B0B1D43203A5Q35662191-AC019F3B-7741-4FE3-ABEE-6174EFE4C9B4Q35889678-F567339F-DB0F-4294-BD70-EF80DCB5C067Q36310191-E917FFE4-D5EB-4205-BADC-898875E2DA1BQ36386871-F322F453-2626-4668-88A0-8E014B5E7C2EQ37109643-EF345831-24E1-476B-8596-D903C5315E84Q37131378-B00F44FB-E97B-4ED0-A023-F004D4C44643Q37186471-E6750715-AD98-4EAF-A428-5949FC9C7544Q37263046-D59F2A4C-0549-4C54-B5AD-6C09A4515036Q37347130-183F7687-596D-4C51-ABA1-D2034025EA8FQ37526989-E8D28593-94D8-4230-BAF6-F2C55661C6EFQ37660353-CE846637-7B7E-47E9-A769-D9006F914B39Q37818228-D6B0DEE6-E24A-4224-9BB4-46734099E57DQ38884705-4D1ED3B2-A454-4EAB-A58D-D8046DDF10CCQ39240242-12160CEB-5EB6-4E1C-89C8-7906DB60D6F4Q39500625-8C2BAB4C-2A0D-408C-B4CB-44CC78B0EB56Q44358008-6BBB5845-F759-44EA-9791-F76B7D7463A5Q46102824-8128D0E4-21B2-490F-947F-5BC147B50F81Q46810982-EA2FD8EA-D36F-46D6-A1F4-791799DBF37CQ52689274-80CE643D-A88C-4F62-8E72-4836EB17E35EQ58690262-1F215F4B-2584-4288-AA4F-5560810797D7
P2860
Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects of estrogen receptor e ...... s of death from breast cancer.
@en
Effects of estrogen receptor e ...... s of death from breast cancer.
@nl
type
label
Effects of estrogen receptor e ...... s of death from breast cancer.
@en
Effects of estrogen receptor e ...... s of death from breast cancer.
@nl
prefLabel
Effects of estrogen receptor e ...... s of death from breast cancer.
@en
Effects of estrogen receptor e ...... s of death from breast cancer.
@nl
P1476
Effects of estrogen receptor e ...... es of death from breast cancer
@en
P2093
Ismail Jatoi
William F Anderson
P2860
P2888
P304
P356
10.1007/S10549-006-9231-Y
P407
P577
2006-05-10T00:00:00Z